Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax grows, but more slowly than its trailing trend

Q2 FY2026 income before tax of $70.99M rose 37.3% year over year, behind the +125.3% change in trailing-twelve-month income before tax. Sequentially, it fell 11.5% from the prior quarter.

Context

  • Income before tax amounted to 4.6% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +37.3% toward the trailing-twelve-month pace of +125.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$70.99M-11.5% QoQ
Last fiscal yearDec 2025
$139.21M+353.0% YoY
LTMJun 2026
$201.18M+125.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.3%——
1 year+353.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
139.21M USD
Year-over-year change
+353.0%
4-year CAGR
+45.1%

Income Before Tax vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +125.3% is the 3rd highest of 11, against a peer median of +20.9%.
  • Income before tax amounts to 6.5% of revenue for AMRX, versus a peer median of 11.6%.
AMRX Competitors
Income Before Tax for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹35.27B INR-53.7%-1.5%10.6%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$720M USD+1128.6%—4.2%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$393M USD+88.9%—29.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$201.18M USD+125.3%—6.5%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$116.03M USD+521.0%—12.6%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$102.81M USD-40.5%+2.5%14.3%
EBSEmergent BioSolutions Inc.LTM Mar 2026$3.5M USD+105.6%—0.5%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$7.22M USD-117.2%—17.2%
VTRSViatris Inc.LTM Jun 2026-$662.2M USD+82.3%—4.5%
BHCBausch Health Companies Inc.LTM Jun 2026-$732M USD-360.5%—6.7%
PRGOPerrigo Company plcLTM Jun 2026-$1.61B USD-1660.9%—38.9%
Peer median (excluding AMRX) —+20.9%+0.5%11.6%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.